1799711-25-3 Usage
General Description
N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide trifluoroacetate salt is a complex chemical compound used in pharmaceutical and research applications. It is composed of a combination of organic compounds, including an amine (4-aminobutyl), a piperidine derivative (2-(2,6-dioxopiperidin-3-yl)), an isoindolinone (1,3-dioxoisoindolin-4-yl), and trifluoroacetate salt. N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide trifluoroacetate salt may have potential biological activities due to the presence of the amine and piperidine moieties, and its trifluoroacetate salt form may enhance solubility and stability. It may be utilized in drug development, medicinal chemistry, and biochemical research for its potential therapeutic effects. Further studies and evaluations are necessary to determine its full chemical and pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1799711-25-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,9,9,7,1 and 1 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1799711-25:
(9*1)+(8*7)+(7*9)+(6*9)+(5*7)+(4*1)+(3*1)+(2*2)+(1*5)=233
233 % 10 = 3
So 1799711-25-3 is a valid CAS Registry Number.
1799711-25-3Relevant articles and documents
Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91
Hanafi, Maha,Chen, Xinde,Neamati, Nouri
, p. 1626 - 1648 (2021/02/27)
Napabucasin, undergoing multiple clinical trials, was reported to inhibit the signal transducer and transcription factor 3 (STAT3). To better elucidate its mechanism of action, we designed a napabucasin-based proteolysis targeting chimera (PROTAC), XD2-149 that resulted in inhibition of STAT3 signaling in pancreatic cancer cell lines without inducing proteasome-dependent degradation of STAT3. Proteomics analysis of XD2-149 revealed the downregulation of the E3 ubiquitin-protein ligase ZFP91. XD2-149 degrades ZFP91 with DC50 values in the nanomolar range. The cytotoxicity of XD2-149 was significantly, but not fully, reduced with ZFP91 knockdown providing evidence for its multi-targeted mechanism of action. The NQO1 inhibitor, dicoumarol, rescued the cytotoxicity of XD2-149 but not ZFP91 degradation, suggesting that the NQO1-induced cell death is independent of ZFP91. ZFP91 plays a role in tumorigenesis and is involved in multiple oncogenic pathways including NF-κB and HIF-1α.
